Inhibition of ras oncogenic activity by ras protooncogenes

Roberto Diaz, Jeffrey Lue, Jeremy Mathews, Andrew Yoon, Daniel Ahn, Antonio Garcia-España, Peter Leonardi, Marcelo P. Vargas, Angel Pellicer

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Point mutations in ras genes have been found in a large number and wide variety of human tumors. These oncogenic Ras mutants are locked in an active GTP-bound state that leads to a constitutive and deregulated activation of Ras function. The dogma that ras oncogenes are dominant, whereby the mutation of a single allele in a cell will predispose the host cell to transformation regardless of the presence of the normal allele, is being challenged. We have seen that increasing amounts of Ras protooncogenes are able to inhibit the activity of the N-Ras oncogene in the activation of Elk in NIH 3T3 cells and in the formation of foci. We have been able to determine that the inhibitory effect is by competition between Ras protooncogenes and the N-Ras oncogene that occurs first at the effector level at the membranes, then at the processing level and lastly at the effector level in the cytosol. In addition, coexpression of the N-Ras protooncogene in thymic lymphomas induced by the N-Ras oncogene is associated with increased levels of p107, p130 and cyclin A and decreased levels of Rb. In the present report, we have shown that the N-Ras oncogene is not truly dominant over Ras protooncogenes and their competing activities might be depending on cellular context.

Original languageEnglish (US)
Pages (from-to)241-248
Number of pages8
JournalInternational Journal of Cancer
Volume113
Issue number2
DOIs
StatePublished - Jan 10 2005
Externally publishedYes

Fingerprint

ras Genes
Alleles
Cyclin A
NIH 3T3 Cells
Guanosine Triphosphate
Point Mutation
Cytosol
Lymphoma
Mutation
Membranes
Neoplasms

Keywords

  • N-Ras
  • Oncogene inhibition
  • Protooncogene
  • Ras effectors
  • Ras processing

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Diaz, R., Lue, J., Mathews, J., Yoon, A., Ahn, D., Garcia-España, A., ... Pellicer, A. (2005). Inhibition of ras oncogenic activity by ras protooncogenes. International Journal of Cancer, 113(2), 241-248. https://doi.org/10.1002/ijc.20563

Inhibition of ras oncogenic activity by ras protooncogenes. / Diaz, Roberto; Lue, Jeffrey; Mathews, Jeremy; Yoon, Andrew; Ahn, Daniel; Garcia-España, Antonio; Leonardi, Peter; Vargas, Marcelo P.; Pellicer, Angel.

In: International Journal of Cancer, Vol. 113, No. 2, 10.01.2005, p. 241-248.

Research output: Contribution to journalArticle

Diaz, R, Lue, J, Mathews, J, Yoon, A, Ahn, D, Garcia-España, A, Leonardi, P, Vargas, MP & Pellicer, A 2005, 'Inhibition of ras oncogenic activity by ras protooncogenes', International Journal of Cancer, vol. 113, no. 2, pp. 241-248. https://doi.org/10.1002/ijc.20563
Diaz R, Lue J, Mathews J, Yoon A, Ahn D, Garcia-España A et al. Inhibition of ras oncogenic activity by ras protooncogenes. International Journal of Cancer. 2005 Jan 10;113(2):241-248. https://doi.org/10.1002/ijc.20563
Diaz, Roberto ; Lue, Jeffrey ; Mathews, Jeremy ; Yoon, Andrew ; Ahn, Daniel ; Garcia-España, Antonio ; Leonardi, Peter ; Vargas, Marcelo P. ; Pellicer, Angel. / Inhibition of ras oncogenic activity by ras protooncogenes. In: International Journal of Cancer. 2005 ; Vol. 113, No. 2. pp. 241-248.
@article{e23d3328d3e64fe88091d3e1cd6b6976,
title = "Inhibition of ras oncogenic activity by ras protooncogenes",
abstract = "Point mutations in ras genes have been found in a large number and wide variety of human tumors. These oncogenic Ras mutants are locked in an active GTP-bound state that leads to a constitutive and deregulated activation of Ras function. The dogma that ras oncogenes are dominant, whereby the mutation of a single allele in a cell will predispose the host cell to transformation regardless of the presence of the normal allele, is being challenged. We have seen that increasing amounts of Ras protooncogenes are able to inhibit the activity of the N-Ras oncogene in the activation of Elk in NIH 3T3 cells and in the formation of foci. We have been able to determine that the inhibitory effect is by competition between Ras protooncogenes and the N-Ras oncogene that occurs first at the effector level at the membranes, then at the processing level and lastly at the effector level in the cytosol. In addition, coexpression of the N-Ras protooncogene in thymic lymphomas induced by the N-Ras oncogene is associated with increased levels of p107, p130 and cyclin A and decreased levels of Rb. In the present report, we have shown that the N-Ras oncogene is not truly dominant over Ras protooncogenes and their competing activities might be depending on cellular context.",
keywords = "N-Ras, Oncogene inhibition, Protooncogene, Ras effectors, Ras processing",
author = "Roberto Diaz and Jeffrey Lue and Jeremy Mathews and Andrew Yoon and Daniel Ahn and Antonio Garcia-Espa{\~n}a and Peter Leonardi and Vargas, {Marcelo P.} and Angel Pellicer",
year = "2005",
month = "1",
day = "10",
doi = "10.1002/ijc.20563",
language = "English (US)",
volume = "113",
pages = "241--248",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Inhibition of ras oncogenic activity by ras protooncogenes

AU - Diaz, Roberto

AU - Lue, Jeffrey

AU - Mathews, Jeremy

AU - Yoon, Andrew

AU - Ahn, Daniel

AU - Garcia-España, Antonio

AU - Leonardi, Peter

AU - Vargas, Marcelo P.

AU - Pellicer, Angel

PY - 2005/1/10

Y1 - 2005/1/10

N2 - Point mutations in ras genes have been found in a large number and wide variety of human tumors. These oncogenic Ras mutants are locked in an active GTP-bound state that leads to a constitutive and deregulated activation of Ras function. The dogma that ras oncogenes are dominant, whereby the mutation of a single allele in a cell will predispose the host cell to transformation regardless of the presence of the normal allele, is being challenged. We have seen that increasing amounts of Ras protooncogenes are able to inhibit the activity of the N-Ras oncogene in the activation of Elk in NIH 3T3 cells and in the formation of foci. We have been able to determine that the inhibitory effect is by competition between Ras protooncogenes and the N-Ras oncogene that occurs first at the effector level at the membranes, then at the processing level and lastly at the effector level in the cytosol. In addition, coexpression of the N-Ras protooncogene in thymic lymphomas induced by the N-Ras oncogene is associated with increased levels of p107, p130 and cyclin A and decreased levels of Rb. In the present report, we have shown that the N-Ras oncogene is not truly dominant over Ras protooncogenes and their competing activities might be depending on cellular context.

AB - Point mutations in ras genes have been found in a large number and wide variety of human tumors. These oncogenic Ras mutants are locked in an active GTP-bound state that leads to a constitutive and deregulated activation of Ras function. The dogma that ras oncogenes are dominant, whereby the mutation of a single allele in a cell will predispose the host cell to transformation regardless of the presence of the normal allele, is being challenged. We have seen that increasing amounts of Ras protooncogenes are able to inhibit the activity of the N-Ras oncogene in the activation of Elk in NIH 3T3 cells and in the formation of foci. We have been able to determine that the inhibitory effect is by competition between Ras protooncogenes and the N-Ras oncogene that occurs first at the effector level at the membranes, then at the processing level and lastly at the effector level in the cytosol. In addition, coexpression of the N-Ras protooncogene in thymic lymphomas induced by the N-Ras oncogene is associated with increased levels of p107, p130 and cyclin A and decreased levels of Rb. In the present report, we have shown that the N-Ras oncogene is not truly dominant over Ras protooncogenes and their competing activities might be depending on cellular context.

KW - N-Ras

KW - Oncogene inhibition

KW - Protooncogene

KW - Ras effectors

KW - Ras processing

UR - http://www.scopus.com/inward/record.url?scp=10344242952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10344242952&partnerID=8YFLogxK

U2 - 10.1002/ijc.20563

DO - 10.1002/ijc.20563

M3 - Article

C2 - 15386411

AN - SCOPUS:10344242952

VL - 113

SP - 241

EP - 248

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -